Colgate's $1 Billion Brand Sale Is a Signal, Not a Crisis

Colgate-Palmolive is quietly asking Goldman Sachs to find buyers for Softsoap, Irish Spring, and Speed Stick. Sources tell Reuters the brands could fetch more than $1 billion. The company declined to comment.

The brands are not failures. They are household names with decades of shelf presence. But the brands sit inside a larger problem management has been circling for months: North American organic sales fell 3% in the most recent quarter, and the CEO told the Barclays investor conference this week that fixing the domestic business requires a "long-term turnaround."

The divestiture is not a crisis sale. It is a signal. When a company with a 130-year dividend track record and a $73 billion market value starts asking what its mass-market soap brands are actually worth, the question for investors is no longer whether the headline is dramatic enough. It is whether the rest of the portfolio has similar cracks underneath.

The brands on the block and what they actually earn

Softsoap, Irish Spring, and Speed Stick fall inside Colgate's personal care unit — deodorants, bar and liquid soaps, shower gels, and skin care. That unit accounted for roughly 17% of 2025 net sales, or approximately $3.5 billion. The entire oral, personal, and home care segment brought in $15.8 billion last year.

Personal care is not Colgate's crown jewel. Oral care is — with 41% global toothpaste market share and the kind of pricing power that comes from being the default in a bathroom routine. Personal care is the business where branded names compete against each other and against store brands on crowded shelves. Speed Stick deodorant and Irish Spring body wash face private-label alternatives that retailers now push harder, especially as consumers tighten their spending.

A $1 billion valuation on a handful of these brands suggests they generate roughly $150–200 million in annual revenue, sold at a low-single-digit multiple of sales — a typical exit multiple for mass-market consumer brands without pricing power. The proceeds would be material but not transformational on a company that generated $4.2 billion in operating cash flow last year. The point is not the money. It is the direction of travel.

Where the growth story hides its gap

Colgate's 2025 financials tell two different stories depending on which line you read.

Reported net sales rose 1.4% to $20.4 billion. Base business earnings per share grew 3% to $3.69. The company generated a record $4.2 billion in operating cash flow and returned $2.9 billion to shareholders through dividends and buybacks. On the surface, this is a well-oiled consumer staples compounder.

Now look at North America, where 17% of sales come from. Organic sales in the region fell 2.2% in the first quarter of 2026 and shipments were down 3% in the second quarter. Volume declined 3.2% in Q1 while pricing barely compensated at +1.0%. The CEO described the competitive landscape as "fierce," with consumers trading down to private label and retailers reducing branded inventory.

The growth Colgate reports is happening elsewhere. Latin America grew 14.8% on the surface, but 9.5 points of that was foreign exchange — a temporary currency tailwind. Europe and the Middle East and Africa posted 11.9% reported growth, with 8.5 points from FX. Asia-Pacific showed 8.9% reported growth, with 3.3 points from FX. Strip out currency translation and the organic picture is thin: 5.4% in Latin America, 3.5% in EMEA, 5.6% in Asia-Pacific. These are emerging-market tailwinds, not North American momentum.

The story works until the North America line.

The pattern: write down, then sell

This is not the first time Colgate has had to reconcile what it paid for a brand with what the brand actually delivers.

In the fourth quarter of 2025, the company recorded a $794 million after-tax impairment charge — $919 million before tax — on goodwill and intangible assets related to its skin health business, centered on the French skincare brand Filorga, which Colgate acquired in 2019. The cause: lower-than-expected category growth and weaker performance, particularly in China. The company lowered its outlook for the business but said it continues to believe in the brand's prospects.

The sequence is worth sitting with. Colgate buys a brand at a premium. The brand underperforms. Management writes down the accounting value by nearly $1 billion and then, less than a year later, begins exploring divestitures of other underperforming brands in an adjacent category. The $794 million impairment is a non-cash accounting entry — it does not affect operating cash flow or the ability to pay dividends. But it is management's formal admission, in filing language, that the economics of at least one portfolio segment are worse than the purchase price implied.

A single impairment is a business judgment. Two portfolio corrections in a year — one on skin health, one on mass personal care — is a pattern. The question is how many more segments are carrying expectations the market has not yet confronted.

The capital structure underneath

Colgate's balance sheet gives context to why the company can afford to sell brands without panicking — and also reveals why it may want to.

The company carries $16.2 billion in total debt against $1.4 billion in cash, for net debt of roughly $6.5 billion. Shareholders' equity stands at $566 million — a number that looks alarming until you understand it. Heavy, sustained share repurchases have shrunk the share count dramatically, pulling retained earnings down through treasury stock accounting. The $5 billion buyback program authorized in March 2025 sits on top of years of similar authorizations. Colgate has been returning cash to shareholders at a pace that compresses the equity base even as operating cash flow grows.

The debt-to-equity ratio prints at nearly 14x, which is a function of the thin equity base rather than a reflection of actual leverage risk. Colgate's free cash flow of $3.9 billion over the trailing twelve months easily covers interest and debt service. The company generates more than enough cash to fund dividends, modest buybacks, and capex. But the capital structure is levered, and the board has signaled that divestiture proceeds would go toward debt reduction and shareholder returns.

This matters because it shows management's priorities. The company is simultaneously growing debt, returning cash, and now potentially shrinking its asset base. It is not a distress signal — Colgate's cash flows are genuine and durable — but it does mean there is limited dry powder to invest in turning around the brands it keeps. If the strategy is "sell the laggards and focus on the leaders," the leaders need to grow fast enough to offset the lost revenue.

What the valuation is pricing in

Colgate trades at a price-to-earnings ratio of 34x, well above Procter & Gamble at 21x and Unilever at 12x. The stock has gained 10% year-to-date and sits near its 52-week high of $99. The premium to peers reflects Colgate's long dividend history, its oral care moat, and the market's expectation of steady, compounding earnings growth under the company's stated 2030 strategy.

A 34x multiple demands consistency. At that price, investors are paying for Colgate to deliver on the innovation pipeline, the AI-driven pricing tools, the emerging-market expansion, and the brand investment strategy that management laid out at the Barclays conference. They are not paying for a company that sells brands to cover the gap.

A $1 billion divestiture represents roughly 1.4% of market capitalization. It is not a valuation-threatening event on its own. But the earnings impact depends on what those brands contribute today in operating profit, and whether the rest of the portfolio can grow into the hole. If Softsoap, Irish Spring, and Speed Stick generate $100–150 million in combined operating profit — a rough estimate based on typical personal care margins — that is roughly 2–3% of reported operating income. The remaining portfolio needs to absorb that loss without missing the double-digit EPS growth the company has guided toward for 2026.

The shareholder invoice

This is not a fraud story. There is no hidden number, no footnote that reverses the earnings, no counterparty that disappears. The evidence ladder sits at Level Two: management has acknowledged North American weakness publicly, the earnings filings confirm volume decline in the domestic market, and the company is now acting on a portfolio adjustment that the market will need to digest.

The shareholder invoice has three cases:

Resolved (the pruning works): Colgate sells the brands for $1 billion, uses the proceeds to reduce debt, and reallocates resources to oral care, premium personal care, and Hill's Pet Nutrition. North America stabilizes as competition moderates. The stock's 34x multiple is justified if organic growth in the remaining portfolio hits the mid-single digits the company has guided. This is the management case.

Persistent but lawful (the decline continues): The divestiture removes brands that were already losing share, but the underlying dynamic — consumer trade-down, private-label encroachment, and retail channel shifts — continues to erode the brands Colgate keeps. Revenue growth stays FX-dependent, North America remains flat or negative organically, and the company compensates with pricing that eventually hits a ceiling. At 34x, the stock is vulnerable to multiple compression if growth disappoints for another two quarters.

Material portfolio reckoning (more brands follow): The personal care divestiture is the first of several. If home care or other segments face similar volume pressure, the company could face a more aggressive downsizing cycle — one that shrinks revenue, complicates the growth story, and challenges the premium the market currently applies. The $794 million Filorga impairment was the first warning that acquisition-driven growth does not always compound.

The next filing to watch is Colgate's third-quarter earnings, expected in late October. The key numbers: North America organic sales, personal care segment volume, and any updated commentary on the divestiture timeline. If domestic volume continues to decline while management raises guidance on the remaining portfolio, the pruning narrative strengthens. If volume falls further without an offsetting plan, the valuation premium becomes the real risk.

The number is not proof of trouble. It is the door.